Abstract
A prospective, randomized, open comparison of three 1 g doses of cefmetazole with three 2 g doses of cefoxitin for non-elective Caesarean section was performed. Sixty-nine patients were evaluated. The two groups were comparable with respect to labout characteristics that might influence risk of postoperative infectious morbidity. Similarly, the nature of the bacterial contamination/infection of the amniotic fluid at the time of Caesarean section was comparable in the two groups. The only infectious morbidity noted was endomyometritis. The incidence was the same in both groups, 5/50 (10%) in the cefmetazole group and 2/19 (10.5%) in the cefoxitin group. Febrile morbidity, as reflected in the fever index, was not significantly different between the groups, 10.2 ± 18.5 degree hours in the cefmetazole group and 7.5 ± 11.7 degree hours in the cefoxitin group. Cefmetazole to be equivalent to cefoxitin in reducing post-Caesarean section endomyometritis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 97-91 |
| Number of pages | 7 |
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 23 |
| Issue number | SUPPL. D |
| State | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Microbiology
- Pharmacology
Cite this
Prophylaxis in caesarean section with cefmetazole and cefoxitin. / Crombleholme, W. R.; Green, J. R.; Ohm-Smith, M.; DeKay, V.; Klaisle, C.; Luft, J.; Robbie, M.; Dahrouge, D.; Sweet, Richard L.
In: Journal of Antimicrobial Chemotherapy, Vol. 23, No. SUPPL. D, 1989, p. 97-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prophylaxis in caesarean section with cefmetazole and cefoxitin
AU - Crombleholme, W. R.
AU - Green, J. R.
AU - Ohm-Smith, M.
AU - DeKay, V.
AU - Klaisle, C.
AU - Luft, J.
AU - Robbie, M.
AU - Dahrouge, D.
AU - Sweet, Richard L
PY - 1989
Y1 - 1989
N2 - A prospective, randomized, open comparison of three 1 g doses of cefmetazole with three 2 g doses of cefoxitin for non-elective Caesarean section was performed. Sixty-nine patients were evaluated. The two groups were comparable with respect to labout characteristics that might influence risk of postoperative infectious morbidity. Similarly, the nature of the bacterial contamination/infection of the amniotic fluid at the time of Caesarean section was comparable in the two groups. The only infectious morbidity noted was endomyometritis. The incidence was the same in both groups, 5/50 (10%) in the cefmetazole group and 2/19 (10.5%) in the cefoxitin group. Febrile morbidity, as reflected in the fever index, was not significantly different between the groups, 10.2 ± 18.5 degree hours in the cefmetazole group and 7.5 ± 11.7 degree hours in the cefoxitin group. Cefmetazole to be equivalent to cefoxitin in reducing post-Caesarean section endomyometritis.
AB - A prospective, randomized, open comparison of three 1 g doses of cefmetazole with three 2 g doses of cefoxitin for non-elective Caesarean section was performed. Sixty-nine patients were evaluated. The two groups were comparable with respect to labout characteristics that might influence risk of postoperative infectious morbidity. Similarly, the nature of the bacterial contamination/infection of the amniotic fluid at the time of Caesarean section was comparable in the two groups. The only infectious morbidity noted was endomyometritis. The incidence was the same in both groups, 5/50 (10%) in the cefmetazole group and 2/19 (10.5%) in the cefoxitin group. Febrile morbidity, as reflected in the fever index, was not significantly different between the groups, 10.2 ± 18.5 degree hours in the cefmetazole group and 7.5 ± 11.7 degree hours in the cefoxitin group. Cefmetazole to be equivalent to cefoxitin in reducing post-Caesarean section endomyometritis.
UR - http://www.scopus.com/inward/record.url?scp=0024565734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024565734&partnerID=8YFLogxK
M3 - Article
C2 - 2722729
AN - SCOPUS:0024565734
VL - 23
SP - 97
EP - 91
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - SUPPL. D
ER -